Shilpa Krishnan of Prabhudas Lilladher on why VA Tech Wabag has the makings of a multibagger
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
Laurus Labs is crucially poised, as investors look forward to its R&D efforts finally paying off
Outstanding companies that exemplify the power of Indian enterprise
Vishnukant Bhutada’s big bet on oncology has catapulted Shilpa Medicare into the global generics space
The time has come for Shilpa Medicare to reap the benefits of the hard work done by its management over the past few years
Tano Capital is cashing in some of its chips at Shilpa Medicare
The steel re-rolling industry has all but flattened out. Can government intervention save the units?
Demographics may dominate investment returns for the next few decades
A few start-ups are making medical access easier and doctors technology-savvy
India's most reticent billionaire is betting his money on the alternative energy space and here's why
Vallum Capital Advisors' Manish Bhandari foresees a bright future for oncology specialist Shilpa Medicare
The site is meant to serve as a digital meeting place for foodies and food professionals.